

PRESS RELEASE

Beactica nominated as “Technology Rising Star” by Deloitte

Uppsala, Sweden, 11 October 2011

Beactica, the leading Swedish fragment-based drug discovery company spun out from Uppsala University announces that it is amongst 25 companies nominated as “Technology Rising Stars” by management consultants Deloitte.

“We are delighted to be one of the 25 fastest growing new technology companies in Sweden” says Per Källblad, CEO of Beactica. “This nomination illustrates the world-leading calibre of our scientific team and the quality of the drug discovery technology platform we have created”.

Deloitte’s annual national Rising Star award identifies new fast-growth technology companies and is part of the Technology Fast 50 program. It ranks new technology companies from all sectors on the basis of growth in revenues over the past three years. Beactica has grown more than 500% in this period.

Beactica uses its proprietary technology platform Sprint™ to accelerate and improve drug discovery success for leading pharmaceutical companies, working in important disease areas such as cancer, brain disorders and infectious diseases.

Looking forward Per Källblad said that Beactica will continue to grow in Uppsala, putting further resources into advancing the scope of its Sprint™ platform and deepening its value-generating collaborations with pharmaceutical industry leaders.

For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80.

About Beactica

Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The Company offers expertise and services in the area of surface plasmon resonance (SPR) biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using its proprietary Sprint™ platform. Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR biosensor-based small molecule drug discovery. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes. The company has its headquarter in Uppsala, Sweden. For more information, please visit www.beactica.com.